These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 8769189)
41. Experience with clinical use of Sandimmun Neoral in renal transplant patients. Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692 [No Abstract] [Full Text] [Related]
42. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Cooney GF; Lum BL; Meligeni JA; Dunn SP Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222 [No Abstract] [Full Text] [Related]
44. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433 [TBL] [Abstract][Full Text] [Related]
45. Case reports on conversion to Neoral therapy in renal transplant patients. Curtis JJ Transplant Proc; 1996 Aug; 28(4):2221-2; discussion 2218. PubMed ID: 8769205 [No Abstract] [Full Text] [Related]
46. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population. Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007 [No Abstract] [Full Text] [Related]
47. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes. Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268 [No Abstract] [Full Text] [Related]
48. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral. Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676 [No Abstract] [Full Text] [Related]
49. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Grant D; Rochon J; Levy G Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208 [No Abstract] [Full Text] [Related]
50. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group. Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194 [No Abstract] [Full Text] [Related]
51. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients. Lee KL; Lee KT; Chung HM; Lin YP Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545 [No Abstract] [Full Text] [Related]
52. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID; Thomson M; Kelly DA Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349 [TBL] [Abstract][Full Text] [Related]
53. Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients. Vernillet L; Kovarik JM; Freiburghaus R; Schaub P; Mueller EA; Niederberger W; Zehender H Transplant Proc; 1994 Oct; 26(5):2964-8. PubMed ID: 7940936 [No Abstract] [Full Text] [Related]
55. Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Superina RA; Strong DK; Acal LA; DeLuca E Transplant Proc; 1994 Oct; 26(5):2979-80. PubMed ID: 7940940 [No Abstract] [Full Text] [Related]
56. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral. Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994 [No Abstract] [Full Text] [Related]
57. Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience. Goh BL; Jalil R; Koh SN; Chua CT; Tan SY Transplant Proc; 1998 Nov; 30(7):3535-6. PubMed ID: 9838548 [No Abstract] [Full Text] [Related]
58. Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD Transplant Proc; 1996 Aug; 28(4):2143-6. PubMed ID: 8769182 [No Abstract] [Full Text] [Related]
59. Experience with new cyclosporine formulations: Consupren and Neoral in renal transplant patients. Barbari A; Stephan A; Kamel G; Kilany H; Masri MA Transplant Proc; 1997 Nov; 29(7):2941-4. PubMed ID: 9365622 [No Abstract] [Full Text] [Related]
60. A study to assess the efficacy, tolerability, and safety of a new oral formulation of Sandimmun--Sandimmun Neoral--in stable renal transplant patients. Rosental R; Bicans J; Berzina R; Zezina L Transplant Proc; 1995 Dec; 27(6):3436-7. PubMed ID: 8540038 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]